What top creators are saying about Tempus AI, Inc.(TEM)

Reported EPS of $0.07 versus an expected loss of $0.08 and revenue of $4.11 billion versus $4.09 billion; shares rose after the report.

Mentioned as a possible non-AI sector area to watch, without company-specific analysis.

Mentioned in passing without specific investment analysis or a price target.

The guest was bullish on medical AI and Tempus's potential to combine software with health data, while noting no revenue forecast or timeline.

Cited as an example of a company involved in AI-related healthcare changes, though the discussion did not establish that it would capture the opportunity.

Identified as an attractive asymmetric biotech/AI growth candidate for out-of-the-money call option strategies.

Attractive long candidate due to potential acquisition interest from large tech firms seeking proprietary clinical data pipelines.

Gained 15%–18% as a secondary beneficiary due to its genomic data and precision medicine partnership with Moderna.

Selected as a high-potential application-layer software beneficiary in the AI ecosystem.

Cited as a losing play that dropped over 25%, highlighting current volatility in the high-growth AI space.